Abstract
On Jan 13, 2012, the UK National Institute for Health and Clinical Excellence (NICE) published guidance1 recommending nilotinib for the treatment of the chronic and accelerated phases of chronic myeloid leukaemia (CML) that is resistant or intolerant to standard-dose imatinib. Dasatinib, is not recommended for treatment of chronic, accelerated, or blast-crisis phase CML in adults with imatinib intolerance or whose CML is resistant to treatment with standard-dose imatinib. High-dose imatinib is not recommended for the treatment of chronic, accelerated, or blast-crisis phase Philadelphia-chromosome-positive CML that is resistant to standard-dose imatinib.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
